Saturday 17 October 2026 Export AYTU’s income statement to Excel — free account

Aytu BioPharma, Inc.

AYTU Healthcare Drug Manufacturers Specialty & Generic

Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.

2.04 0.03 +1.49%

Follow AYTU

Alert me

Market cap: $21.8M
P/E: 0.0×
Fwd P/E: −9.2×
Dividend yield: —
F-score: 3/9
Altman Z: −4.04
Beneish M: −3.48
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
P/E ratio Full definition →	+8 more quarters Free account	0.00	0.00	0.00	0.00
P/S ratio Full definition →		0.28	0.42	0.51	0.46
P/FCF ratio Full definition →		0.00	0.00	18.22	8.19
P/Operating CF Full definition →		(28.72)	7.10	(6.86)	6.01
P/B ratio Full definition →		0.77	1.84	0.82	0.75
Price to Tangible BV Full definition →		0.00	0.00	0.00	0.00
EV/Sales Full definition →		0.19	0.27	0.42	0.30
EV/EBITDA Full definition →		0.00	0.00	0.00	0.00
EV/Operating CF Full definition →		(9.01)	(28.57)	14.18	5.25
EV/FCF Full definition →		(13.29)	(30.74)	15.11	5.32
Quick Ratio Full definition →		1.00	0.93	0.85	0.90
Current Ratio Full definition →		1.23	1.16	1.12	1.13
Net Debt/EBITDA Full definition →		8.11	8.61	1.68	(24.94)
Debt/Assets Full definition →		21.74%	17.16%	19.53%	16.22%
Debt/Equity Full definition →		1.17	1.47	0.62	0.48
Asset Turnover Full definition →		0.53	0.53	0.48	0.50
Operating CF/Net income Full definition →		(0.31)	(0.35)	0.74	(293.73)
Capex/Depreciation Full definition →		0.00	(0.02)	0.00	(0.01)
Interest Coverage Full definition →		(2.91)	(3.52)	(9.32)	(2.03)
Research and Development Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →		73.78%	72.98%	87.84%	64.73%
Intangible Assets out of Total Assets Full definition →		0.33	0.36	0.38	0.39
Share Based Compensation of Revenue Full definition →		0.82%	1.87%	1.19%	0.91%
Graham Net Nets Full definition →		(1.17)	(1.21)	(0.32)	(0.30)
Graham Number Full definition →		0.00	0.00	0.00	0.00
Earnings Yield Full definition →		(102.66%)	(119.62%)	(157.14%)	(63.72%)
Free Cash Flow Yield Full definition →		(5.21%)	(2.12%)	5.49%	12.21%
Revenue per Share Full definition →		1.47	1.51	1.18	1.31
Operating CF per Share Full definition →		(0.07)	0.37	(0.40)	0.36
Capex per Share Full definition →		0.00	0.00	0.00	0.00
Free Cash Flow per Share Full definition →		(0.07)	0.36	(0.40)	0.36
Cash per Share Full definition →		3.46	2.99	2.54	2.14
Shareholders Equity per Share Full definition →		2.45	1.42	3.34	2.86
Interest Debt per Share Full definition →		0.00	0.00	0.00	0.00
Book value per Share Full definition →		2.45	1.42	3.34	2.86
Free Cash Flow Full definition →		(0.62)	3.66	(4.18)	4.39
Working Capital Full definition →		15.12	10.68	7.35	7.10
Capital Expenditures Full definition →		—	(0.02)	0.00	(0.01)
Net Current Asset Value Full definition →		(20.71)	(31.56)	(9.22)	(7.97)
EV/EBIT Full definition →		0.00	0.00	0.00	0.00
Capex to Sales Full definition →		0.00	0.00	0.00	0.00
Price to Operating Income Full definition →		0.00	0.00	0.00	0.00
Other line items
Average Receivables Full definition →		28.19	28.16	30.16	26.97
Average Payables Full definition →		12.93	12.98	12.63	10.94
Average Inventory Full definition →		10.92	9.87	9.26	9.15
Average Assets Full definition →		120.41	119.11	117.95	114.59
Average Common Equity Full definition →		26.50	22.48	35.02	27.12

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026

Stockrow Weekly